Practitioner’s guide to valuation in the pharmaceutical, biotechnology, diagnostics, medical devices and wider life sciences and healthcare sector- get acquainted with state-of-the-art concepts and practices.
Properly valuing drug and biotechnology assets is essential for pharmaceutical enterprises, biotech companies, investors, and other healthcare stakeholders. Valuation provides vital insights to inform high-impact decisions including clinical trial continuation,…
Selecting the appropriate discount rate is essential for pharmaceutical and biotechnology valuations. The discount rate is one of the key drivers of valuation and it has varied usage in the…
Valuing early-stage healthcare and life sciences startups presents unique challenges due to their lack of revenue, high-risk profiles, and massive capital needs. Conventional methods often fail to capture the potential…
Determining the valuation of pharmaceutical and biotechnology companies is a crucial exercise to inform high-impact decisions including organic investments and prioritization, licensing deals, and mergers and acquisitions. EBITDA multiples are…
Valuation of biotech companies, assets, and programs is often required for a multitude of purposes. The biotech valuation multiples is a comparable companies valuation method and it provides a market-based…
When valuing a private or public biotech company using market multiples, one of the most critical first steps is 'comparable companies selection' which involves devising a valuation peer group -…
Market size is one of the critical elements in the life sciences commercial due diligence, new product planning, assessments for licensing, partnering and investments. Computing from the first principle is…
In the pharmaceutical and biotechnology industry (referred to collectively as biopharma), almost all valuation and investment decisions decisions are based on DCF-based risk-adjusted net present value. Indeed, several other financial…
Determining the appropriate addressable market is often one of the critical success factors in commercial due diligence, new product planning, and opportunity assessment for healthcare and life sciences businesses. At…
Several stakeholders who have an interest in pharmaceutical assets employ a multitude of methods to conduct valuations. Among various valuation methods, risk-adjusted NPV (rNPV) conducted using discounted cash flow analysis…